Exactech Inc.
http://www.exac.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Exactech Inc.
Teva Starts The Year With Phase III Data And Growth
Teva reported positive Phase III data for a long-acting version of olanzapine for schizophrenia, coinciding with its first quarter sales and earnings release.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
Remibrutinib REMIXes The Itch Record
Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.
Company Information
- Industry
- Distributors
- Contract Manufacturing Organization
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Blue Ortho SAS
- Exactech Australia Pty Ltd
- TPG Capital
- XpandOrtho, Inc.
- Exactech Italia
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice